- $100.33bn
- $119.79bn
- £32.67bn
GSK is two shots away from clean bill of health
Brief: GSK Says US FDA Approves Hibsago For Chronic Hepatitis B
US FDA approves Hibsago for chronic hepatitis B
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
US FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment
Early US flu season, current strain may signal risk for younger people; doctors urge shots
Brief: Jemperli (Dostarlimab-Gxly) Approved In Us As First And Only Immunotherapy For Adults With Msi-H/Dmmr Locally Advanced Rectal Cancer
Brief: FDA Approves GSK's Jemperli As First Immunotherapy For MSI-H/DMMR Rectal Cancer
Jemperli approved in MSI-H/dMMR rectal cancer
Factbox: Major drugmakers turn to China for licensing deals
Ris-Rez positive early data in lung cancer
Brief: GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial
China biotech's ingenuity extends to dealmaking
China biotech's ingenuity extends to dealmaking
Director/PDMR Shareholding
Director/PDMR Shareholding
GSK plans to cut up to 1,217 jobs in Belgium as it begins three-year restructuring plan (updated)
GSK to cut up to 1,217 jobs in Belgium, L'Echo says